Bausch + Lomb Corporation (BLCO) is a Medical - Instruments & Supplies company in the Healthcare sector, currently trading at $16.71. It has a SharesGrow Score of 45/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of BLCO = $94.85 (+467.6% from the current price, the stock appears undervalued). Analyst consensus target is BLCO = $19 (+13.1% upside).
Valuation: BLCO trades at a trailing Price-to-Earnings (P/E) of -16 (S&P 500 average ~25).
Financials: revenue is $5.1B, +10.7%/yr average growth. Net income is $360M (loss), growing at -622.9%/yr. Net profit margin is -7.1% (negative). Gross margin is 58.7% (-1 pp trend).
Balance sheet: total debt is $5.4B against $6.4B equity (Debt-to-Equity (D/E) ratio 0.83, moderate). Current ratio is 1.55 (strong liquidity). Debt-to-assets is 38.3%. Total assets: $14.0B.
Analyst outlook: 7 / 16 analysts rate BLCO as buy (44%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 71/100 (Pass), Growth 48/100 (Partial), Past 25/100 (Fail), Health 50/100 (Partial), Moat 70/100 (Pass), Future 40/100 (Partial), Income 10/100 (Fail).
